Kairos PharmaKAPA +7.48%15 OCF Yield % is -45.80 as of Jun. 30, 2026. GuruFocus rates KAPA with a GF Score™ of 15/100. Among 1,416 Biotechnology companies, Kairos Pharma ranks worse than 83.4% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Kairos Pharma OCF Yield % Related Terms
Kairos Pharma OCF Yield % Historical Data
* Premium members only.
The historical data trend for Kairos Pharma's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kairos Pharma's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kairos Pharma OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kairos Pharma's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Kairos Pharma's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kairos Pharma (KAPA) has a OCF Yield % of -45.80 as of Jun. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Kairos Pharma and its competitors. According to the industry distribution chart, Kairos Pharma ranks #1181 out of 1416 companies in the Biotechnology industry, placing it in the top 83.4%.
Is Kairos Pharma's OCF Yield % too high?
Kairos Pharma's current OCF Yield % is -45.80. Based on the distribution chart, Kairos Pharma ranks #1181 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's OCF Yield % compare to IMNN and HCWB?
According to the Biotechnology industry distribution chart, Kairos Pharma ranks #1181 out of 1416 companies for OCF Yield %. This places Kairos Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Kairos Pharma and its competitors. Kairos Pharma's current OCF Yield % is -45.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current OCF Yield % of -45.80. The current OCF Yield % is -45.80. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current OCF Yield % is -45.80 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score
Get the complete analysis for KAPA
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAPA has been successfully added to your 
